Echosens
21
3
3
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
4.8%
1 terminated/withdrawn out of 21 trials
93.3%
+6.8% vs industry average
0%
0 trials in Phase 3/4
7%
1 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
FibroScan-Reproducibility and Repeatability Study
Role: lead
Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Role: collaborator
Development of a FibroScan Liver Examination Using a Single Probe
Role: lead
Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)
Role: collaborator
Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)
Role: lead
Development of a New Method for Liver Stiffness Measurement Using FibroScan
Role: lead
Validation of the New Vibration-guided FibroScan Examination
Role: lead
Optimization of Spleen VCTE Examinations with FibroScan
Role: lead
Global Research Initiative for Patients Screening on MASH
Role: collaborator
Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.
Role: collaborator
The Visceral Adiposity Measurement and Observation Study
Role: collaborator
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
Role: lead
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
Role: lead
Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination
Role: lead
Spleen Stiffness Measurement With FibroScan
Role: lead
Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery
Role: collaborator
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Role: collaborator
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.
Role: lead
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
Role: collaborator
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
Role: collaborator